Bruker AXS Wins Frost & Sullivan Market Leadership Award in X-ray Diffraction.

BOSTON -- At today's opening of the Materials Research Society's Fall Meeting in Boston, Bruker BioSciences Corporation (NASDAQ: BRKR) announces that Frost & Sullivan has selected the company's Bruker AXS subsidiary for their 2004 Market Leadership Award in X-ray Diffraction instrumentation.

Frost & Sullivan analyst John Weber stated: "Bruker AXS is the recipient of our award for its exemplary leadership in the X-ray Diffraction (XRD) market. Bruker AXS is also a leading participant in several other analytical instrumentation markets, such as X-ray Fluorescence and X-ray Crystallography. Bruker AXS' products find global application in research and production facilities in many leading pharmaceutical, biotechnology, chemical and petrochemical, and semiconductor firms, along with universities. Key markets include advanced materials research, drug discovery and development, elemental and process analysis, as well as structural proteomics. Bruker AXS was early to gauge and understand key customers' changing needs, and now provides one of the widest product portfolios using x-ray technology."

"Bruker AXS' X-ray technologies, best exemplified in their flagship D8 Discover instrument, incorporate high-speed detection systems and high-flux optics that are unprecedented. The latest in Bruker AXS' line, SUPER SPEED SOLUTIONS, and the new NANOSTAR system for nanotechnology applications, are touted to be the fastest of their kind, unrivaled by any other," Weber added.

He concluded: "Research indicates that in 2003 Bruker AXS was the largest X-ray diffractometer manufacturer in the world, accounting for over 30 percent in market share. A strong pipeline of new techniques and strong brand recognition are projected to positively impact the company's position in the X-ray Diffraction market, along with an ever-expanding range of applications."

Frost & Sullivan President Krishna Srinivasan explained: "Understanding customers and offering them comprehensive solutions; modular, turnkey systems; insightful investment into R&D that will ensure a healthy pipeline; acquisition of key techniques and suppliers that enable further penetration into important markets; and commitment to customer service are the factors that make Bruker AXS the worthy recipient of the 2004 Frost & Sullivan Award for Market Leadership in the World X-ray Diffraction Market."

Dr. Frank Burgaezy, Global Product Line Manager for Bruker AXS' XRD Business, commented: "We are very pleased to receive this award, since it is an acknowledgement of our constant efforts to provide our customers with the best x-ray solutions for their analytical needs. Our unique D8 product platform, our cutting edge technologies in X-ray sources, optics and detectors, our leading software packages and, most importantly, our highly skilled and motivated employees, are the backbone of our success. We consider this award as a recognition of our commitment to the future of x-ray analysis."

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.